Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions
Mohammed Hassan Shabrawishi, Abdallah Y Naser, Hassan Alwafi, Ahmad Mansoor Aldobyany, Abdelfattah Ahmed Touman
doi:10.1101/2020.05.08.20095679
Take home message: Prescribing antimalarial medications for patients with COVID-19 was not shown to shorten the disease course nor to accelerate the negative PCR conversion rate.
CONFLICT OF INTEREST The authors have stated explicitly that there are no conflicts of interest in connection with this article.
AUTHORS CONTRIBUTIONS Shabrawishi, Naser, Touman, and Alwafi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Shabrawishi, and Touman had the original idea for this study. Shabrawishi, Naser, Touman, and Alwafi contributed to the design of the study. Shabrawishi and Touman contributed to the data collection. Naser
References
Bai, Yao, Wei, Tian, Chen, Presumed Asymptomatic Carrier Transmission of COVID-19, JAMA
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J of Zjeijang University
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet
Chorin, Dai, Shulman, Wadhwani, Cohen et al., The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARSCoV-2
Ferner, Aronson, Chloroquine and hydroxychloroquine in covid-19, BMJ
For, Control, Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 2020
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents
Gunja, Roberts, Mccoubrie, Lamberth, Simes, Survival after massive hydroxychloroquine overdose, Anaesth Intensive Care
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
Makin, Wendon, Fitt, Portmann, Williams, Fulminant hepatic failure secondary to hydroxychloroquine, Gut
Murphy, Carmichael, Fatal toxic epidermal necrolysis associated with hydroxychloroquine, Clin Exp Dermatol
Rothe, Schunk, Sothmann, Bretzel, Froeschl et al., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany, N Engl J Med
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
{ 'institution': [{'name': 'medRxiv'}],
'indexed': {'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T10:52:14Z', 'timestamp': 1663239134875},
'posted': {'date-parts': [[2020, 5, 11]]},
'group-title': 'Respiratory Medicine',
'reference-count': 23,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'accepted': {'date-parts': [[2020, 5, 11]]},
'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Despite '
'lack of convincing evidence of the efficacy of hydroxychloroquine, it has been suggested to '
'be used for the treatment of SARS-CoV-2 to accelerate the negative virus conversion. We aimed '
'to explore the association between negative nasopharyngeal SARS-CoV-2 PCR clearance and '
'different therapeutic '
'interventions.</jats:p></jats:sec><jats:sec><jats:title>METHODOLOGY</jats:title><jats:p>This '
'was a retrospective cohort study of 93 patients who were admitted to medical ward with a PCR '
'confirmed diagnosis of COVID-19 and met the inclusion criteria in a tertiary hospital in '
'Mecca, Saudi Arabia. There were three interventional subgroups (group A (n=45): who received '
'antimalarial drug only classified as (A1), combined with azithromycin (A2) or combined with '
'antiviral drugs (A3)), and one supportive care group (group B) (n=48). The primary and '
'secondary endpoints of the study were achieving negative SARS-CoV-2 nasopharyngeal PCR sample '
'within five days or less from the start of the intervention and 12 days or less from the '
'diagnose, '
'respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>The mean '
'age of the patients was 43.9 years (SD:15.9). A median time of 3.00 days (IQR:2.00-6.50) '
'needed from the time of starting the intervention/supportive care to the first negative PCR '
'sample. There was no statistically significant difference neither between the percentage of '
'patients in the interventional group and the supportive care group who achieved the primary '
'or the secondary endpoint, nor in the median time needed to achieve the first negative PCR '
'sample '
'(p>0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>Prescribing '
'antimalarial medications was not shown to shorten the disease course nor to accelerate the '
'negative PCR conversion rate.</jats:p></jats:sec>',
'DOI': '10.1101/2020.05.08.20095679',
'type': 'posted-content',
'created': {'date-parts': [[2020, 5, 11]], 'date-time': '2020-05-11T22:25:15Z', 'timestamp': 1589235915000},
'source': 'Crossref',
'is-referenced-by-count': 4,
'title': 'Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic '
'interventions',
'prefix': '10.1101',
'author': [ {'given': 'Mohammed Hassan', 'family': 'Shabrawishi', 'sequence': 'first', 'affiliation': []},
{'given': 'Abdallah Y', 'family': 'Naser', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hassan', 'family': 'Alwafi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ahmad Mansoor', 'family': 'Aldobyany', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Abdelfattah Ahmed',
'family': 'Touman',
'sequence': 'additional',
'affiliation': []}],
'member': '246',
'reference': [ { 'key': '2021011111121549000_2020.05.08.20095679v1.1',
'unstructured': 'World Health Organization. Coronavirus disease 2019 (COVID-19): '
'situation report—70 2020 [Available from: '
'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f82.'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/s01406736(20)30211-7'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.3',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMc2001468'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.4',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.2565'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.5',
'unstructured': 'Chinese national health commission and stat administration of '
'traditional Chinese medicine. Diagnosis and treatment protocol for novel '
'corona viruses pneumonia. 2020.'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.6',
'unstructured': 'Saudi center for disease prevention and control. Quick interim guide to '
'COVID-19 surveillance case definition and disposition. 2020.'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.7',
'unstructured': 'Centre for Disease Control and Prevention. Information for Clinicians on '
'Investigational Therapeutics for Patients with COVID-19 2020 [updated '
'April 25, 2020. Available from: '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.8',
'doi-asserted-by': 'crossref',
'unstructured': 'Colson P , Rolain J , Raoult D . Chloroquine for the 2019 novel '
'coronavirus SARSCoV-2. Int J Antimicrob Agents. 2020.',
'DOI': '10.1016/j.ijantimicag.2020.105923'},
{ 'issue': '4',
'key': '2021011111121549000_2020.05.08.20095679v1.9',
'doi-asserted-by': 'crossref',
'first-page': '105932',
'DOI': '10.1016/j.ijantimicag.2020.105932',
'article-title': 'Chloroquine and hydroxychloroquine as available weapons to fight '
'COVID-19',
'volume': '55',
'year': '2020',
'journal-title': 'Int J Antimicrob Agents'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.10',
'doi-asserted-by': 'crossref',
'first-page': '16',
'DOI': '10.1038/s41421-020-0156-0',
'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is '
'effective in inhibiting SARS-CoV-2 infection in vitro',
'volume': '6',
'year': '2020',
'journal-title': 'Cell Discov'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.11',
'doi-asserted-by': 'crossref',
'unstructured': 'Yao X , Ye F , Zhang M , Cui C , Huang B , Niu P , et al. In Vitro '
'Antiviral Activity and Projection of Optimized Dosing Design of '
'Hydroxychloroquine for the Treatment of Severe Acute Respiratory '
'Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.',
'DOI': '10.1093/cid/ciaa237'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.12',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41422-020-0282-0'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.13',
'doi-asserted-by': 'crossref',
'unstructured': 'Gautret P , Lagier JC , Parola P , Hoang VT , Meddeb L , Mailhe M , et '
'al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: '
'results of an open-label nonrandomized clinical trial. Int J Antimicrob '
'Agents. 2020: 105949.',
'DOI': '10.1016/j.ijantimicag.2020.105949'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.14',
'unstructured': 'Chen J , Liu D , Liu L , Liu P , Xu Q , Xia L . A pilot study of '
'hydroxychloroquine in treatment of patients with common coronavirus '
'disease-19 (COVID-19). J of Zjeijang University. 2020;49(1).'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.15',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.m1432'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.16',
'doi-asserted-by': 'publisher',
'DOI': '10.1177/0310057X0903700112'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.17',
'doi-asserted-by': 'crossref',
'unstructured': 'Chorin E , Dai M , Shulman E , Wadhwani L , Bar Cohen R , Barbhaiya C , '
'et al. The QT interval in patients with SARS-CoV-2 infection treated '
'with hydroxychloroquine/azithromycin. [[Preprint]]. In press 2020.',
'DOI': '10.1101/2020.04.02.20047050'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.18',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/gut.35.4.569'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.19',
'doi-asserted-by': 'publisher',
'DOI': '10.1046/j.1365-2230.2001.00857-3.x'},
{ 'issue': '10229',
'key': '2021011111121549000_2020.05.08.20095679v1.20',
'doi-asserted-by': 'crossref',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'article-title': 'Clinical course and risk factors for mortality of adult inpatients with '
'COVID-19 in Wuhan, China: a retrospective cohort study',
'volume': '395',
'year': '2020',
'journal-title': 'The Lancet'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.21',
'doi-asserted-by': 'crossref',
'unstructured': 'Gautret P , Lagier JC , Parola P , Hoang VT , Meddeb L , Sevestre J , et '
'al. Clinical and microbiological effect of a combination of '
'hydroxychloroquine and azithromycin in 80 COVID-19 patients with at '
'least a six-day follow up: A pilot observational study. Travel Med '
'Infect Dis. 2020: 101663.',
'DOI': '10.1016/j.tmaid.2020.101663'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.22',
'unstructured': 'Saudi Ministry of Health. Protocol for Adults Patients Suspected '
'of/Confirmed with COVID-19 Supportive care and antiviral treatment of '
'suspected or confirmed COVID-19 infection. 2020.'},
{ 'key': '2021011111121549000_2020.05.08.20095679v1.23',
'doi-asserted-by': 'crossref',
'unstructured': 'Magagnoli J , Narendran S , Pereira F , Cummings T , Hardin JW , Sutton '
'SS , et al. Outcomes of hydroxychloroquine usage in United States '
'veterans hospitalized with Covid-19 [Preprint]. In press 2020.',
'DOI': '10.1101/2020.04.16.20065920'}],
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.05.08.20095679',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 1, 14]],
'date-time': '2021-01-14T05:45:13Z',
'timestamp': 1610603113000},
'score': 1,
'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.05.08.20095679'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2020, 5, 11]]},
'references-count': 23,
'URL': 'http://dx.doi.org/10.1101/2020.05.08.20095679',
'relation': {},
'published': {'date-parts': [[2020, 5, 11]]},
'subtype': 'preprint'}
